Literature DB >> 31549947

Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis.

Antonia Valentina Genovese1, Jesper Hagemeier1, Niels Bergsland1, Dejan Jakimovski1, Michael G Dwyer1, Deepa P Ramasamy1, Alexis A Lizarraga1, David Hojnacki1, Channa Kolb1, Bianca Weinstock-Guttman1, Robert Zivadinov1.   

Abstract

Background Atrophied T2 lesion volume at MRI is an imaging measure that reflects the replacement of T2 lesions by cerebrospinal fluid spaces in patients with multiple sclerosis (MS). Purpose To investigate the association of atrophied T2 lesion volume and development of disability progression (DP) and conversion to secondary progressive MS (SPMS). Materials and Methods This retrospective study included 1612 participants recruited from 2006 to 2016 and followed up for 5 years with clinical and MRI examinations. Accumulation of T2 lesion volume, atrophied T2 lesion volume, percentage brain volume change (PBVC), and percentage ventricular volume change (PVVC) were measured. Disability progression and secondary progressive conversion were defined by using standardized guidelines. Analysis of covariance (ANCOVA) adjusted for age and Cox regression adjusted for age and sex were used to compare study groups and explore associations between MRI and clinical outcomes. Results A total of 1314 patients with MS (1006 women; mean age, 46 years ± 11 [standard deviation]) and 124 patients with clinically isolated syndrome (100 women; mean age, 39 years ± 11) along with 147 healthy control subjects (97 women; mean age, 42 years ± 13) were evaluated. A total of 336 of 1314 (23%) patients developed DP, and in 67 of 1213 (5.5%) the disease converted from clinically isolated syndrome (CIS) or relapsing-remitting MS (RRMS) to SPMS. Patients with conversion to DP had higher atrophied T2 lesion volume (+34.4 mm3; 95% confidence interval [CI]: 17.2 mm3, 51.5 mm3; d = 0.27; P < .001) and PBVC (-0.21%; 95% CI: -0.36%, -0.05%; d = 0.19; P = .042) but not PVVC (0.36%; 95% CI: -0.93%, 1.65%; d = 0.04; P = .89) or T2 lesion volume change (-64.5 mm3; 95% CI: -315.2 mm3, 186.3 mm3; d = 0.03; P = .67) when compared with DP nonconverters. ANCOVA showed that atrophied T2 lesion volume was associated with conversion from CIS or RRMS to SPMS (+26.4 mm3; 95% CI: 4.2 mm3, 56.9 mm3; d = 0.23; P = .002) but not PBVC (-0.14%; 95% CI: -0.46%, 0.18%; d = 0.11; P = .66), PVVC (+0.18%; 95% CI: -2.49%, 2.72%; d = 0.01; P = .75), or T2 lesion volume change (-46.4 mm3; 95% CI: -460.8 mm3, 367.9 mm3; d = 0.03; P = .93). At Cox regression analysis, only atrophied T2 lesion volume was associated with the DP (hazard ratio, 1.23; P < .001) and conversion to SPMS (hazard ratio, 1.16; P = .008). Conclusion Atrophied brain T2 lesion volume is a robust MRI marker of MS disability progression and conversion into a secondary progressive disease course. © RSNA, 2019 Online supplemental material is available for this article. See also the editorial by Chiang in this issue.

Entities:  

Mesh:

Year:  2019        PMID: 31549947      PMCID: PMC6823621          DOI: 10.1148/radiol.2019190306

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  40 in total

Review 1.  Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients.

Authors:  Mike P Wattjes; Àlex Rovira; David Miller; Tarek A Yousry; Maria P Sormani; Maria P de Stefano; Mar Tintoré; Cristina Auger; Carmen Tur; Massimo Filippi; Maria A Rocca; Franz Fazekas; Ludwig Kappos; Chris Polman
Journal:  Nat Rev Neurol       Date:  2015-09-15       Impact factor: 42.937

2.  The role of ceramide and SEW 2871 in the transcription of enzymes involved in amyloid b precursor protein metabolism in an experimental model of Alzheimer's disease.

Authors:  Kinga Czubowicz; Sylwia Wójtowicz; Przemysław Leonard Wencel; Robert Piotr Strosznajder
Journal:  Folia Neuropathol       Date:  2018       Impact factor: 2.038

3.  Magnetization transfer ratio measures in normal-appearing white matter show periventricular gradient abnormalities in multiple sclerosis.

Authors:  Zheng Liu; Matteo Pardini; Özgür Yaldizli; Varun Sethi; Nils Muhlert; Claudia A M Wheeler-Kingshott; Rebecca S Samson; David H Miller; Declan T Chard
Journal:  Brain       Date:  2015-03-29       Impact factor: 13.501

Review 4.  Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.

Authors:  Alan J Thompson; Brenda L Banwell; Frederik Barkhof; William M Carroll; Timothy Coetzee; Giancarlo Comi; Jorge Correale; Franz Fazekas; Massimo Filippi; Mark S Freedman; Kazuo Fujihara; Steven L Galetta; Hans Peter Hartung; Ludwig Kappos; Fred D Lublin; Ruth Ann Marrie; Aaron E Miller; David H Miller; Xavier Montalban; Ellen M Mowry; Per Soelberg Sorensen; Mar Tintoré; Anthony L Traboulsee; Maria Trojano; Bernard M J Uitdehaag; Sandra Vukusic; Emmanuelle Waubant; Brian G Weinshenker; Stephen C Reingold; Jeffrey A Cohen
Journal:  Lancet Neurol       Date:  2017-12-21       Impact factor: 44.182

5.  Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis: a case-control study.

Authors:  Robert Zivadinov; Mari Heininen-Brown; Claudiu V Schirda; Guy U Poloni; Niels Bergsland; Christopher R Magnano; Jacqueline Durfee; Cheryl Kennedy; Ellen Carl; Jesper Hagemeier; Ralph H B Benedict; Bianca Weinstock-Guttman; Michael G Dwyer
Journal:  Neuroimage       Date:  2011-07-27       Impact factor: 6.556

6.  Validation of the automated method VIENA: an accurate, precise, and robust measure of ventricular enlargement.

Authors:  Hugo Vrenken; Eline K Vos; W M van der Flier; Ingrid C Sluimer; Keith S Cover; Dirk L Knol; Frederik Barkhof
Journal:  Hum Brain Mapp       Date:  2013-01-30       Impact factor: 5.038

Review 7.  Can imaging techniques measure neuroprotection and remyelination in multiple sclerosis?

Authors:  Robert Zivadinov
Journal:  Neurology       Date:  2007-05-29       Impact factor: 9.910

8.  Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability.

Authors:  J H van Waesberghe; W Kamphorst; C J De Groot; M A van Walderveen; J A Castelijns; R Ravid; G J Lycklama à Nijeholt; P van der Valk; C H Polman; A J Thompson; F Barkhof
Journal:  Ann Neurol       Date:  1999-11       Impact factor: 10.422

9.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

10.  Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration.

Authors:  H Kearney; M A Rocca; P Valsasina; L Balk; J Sastre-Garriga; J Reinhardt; S Ruggieri; A Rovira; C Stippich; L Kappos; T Sprenger; P Tortorella; M Rovaris; C Gasperini; X Montalban; J J G Geurts; C H Polman; F Barkhof; M Filippi; D R Altmann; O Ciccarelli; D H Miller; D T Chard
Journal:  Mult Scler       Date:  2013-06-27       Impact factor: 6.312

View more
  9 in total

1.  MRI biomarkers of disease progression in multiple sclerosis: old dog, new tricks?

Authors:  Yael Barnett; Justin Y Garber; Michael H Barnett
Journal:  Quant Imaging Med Surg       Date:  2020-02

2.  Cortical and phase rim lesions on 7 T MRI as markers of multiple sclerosis disease progression.

Authors:  Constantina A Treaba; Allegra Conti; Eric C Klawiter; Valeria T Barletta; Elena Herranz; Ambica Mehndiratta; Andrew W Russo; Jacob A Sloane; Revere P Kinkel; Nicola Toschi; Caterina Mainero
Journal:  Brain Commun       Date:  2021-06-24

3.  Long-standing multiple sclerosis neurodegeneration: volumetric magnetic resonance imaging comparison to Parkinson's disease, mild cognitive impairment, Alzheimer's disease, and elderly healthy controls.

Authors:  Dejan Jakimovski; Niels Bergsland; Michael G Dwyer; Jesper Hagemeier; Deepa P Ramasamy; Kinga Szigeti; Thomas Guttuso; David Lichter; David Hojnacki; Bianca Weinstock-Guttman; Ralph H B Benedict; Robert Zivadinov
Journal:  Neurobiol Aging       Date:  2020-02-08       Impact factor: 4.673

4.  Decreasing brain iron in multiple sclerosis: The difference between concentration and content in iron MRI.

Authors:  Ferdinand Schweser; Jesper Hagemeier; Michael G Dwyer; Niels Bergsland; Simon Hametner; Bianca Weinstock-Guttman; Robert Zivadinov
Journal:  Hum Brain Mapp       Date:  2020-12-30       Impact factor: 5.038

Review 5.  In vivo imaging of chronic active lesions in multiple sclerosis.

Authors:  Alberto Calvi; Lukas Haider; Ferran Prados; Carmen Tur; Declan Chard; Frederik Barkhof
Journal:  Mult Scler       Date:  2020-09-23       Impact factor: 6.312

6.  Consensus on early detection of disease progression in patients with multiple sclerosis.

Authors:  José E Meca-Lallana; Bonaventura Casanova; Alfredo Rodríguez-Antigüedad; Sara Eichau; Guillermo Izquierdo; Carmen Durán; Jordi Río; Miguel Ángel Hernández; Carmen Calles; José M Prieto-González; José Ramón Ara; Dionisio F Uría; Lucienne Costa-Frossard; Antonio García-Merino; Celia Oreja-Guevara
Journal:  Front Neurol       Date:  2022-07-28       Impact factor: 4.086

Review 7.  The intellectual base and research fronts of IL-37: A bibliometric review of the literature from WoSCC.

Authors:  Ya-Fei Qin; Shao-Hua Ren; Bo Shao; Hong Qin; Hong-da Wang; Guang-Ming Li; Yang-Lin Zhu; Cheng-Lu Sun; Chuan Li; Jing-Yi Zhang; Hao Wang
Journal:  Front Immunol       Date:  2022-07-22       Impact factor: 8.786

Review 8.  Unmet needs and gaps in the identification of secondary progression in multiple sclerosis: a Southern Italy healthcare professionals' perspective.

Authors:  Giacomo Lus; Marco André Bassano; Vincenzo Brescia Morra; Simona Bonavita; Antonio Gallo; Davide Maimone; Laura Malerba; Giorgia Teresa Maniscalco; Francesco Saccà; Giuseppe Salemi; Renato Turrini; Salvatore Cottone; Edoardo Sessa; Maria Buccafusca; Luigi Maria Edoardo Grimaldi
Journal:  Neurol Sci       Date:  2022-09-17       Impact factor: 3.830

9.  Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis.

Authors:  Marcus Sucksdorff; Markus Matilainen; Jouni Tuisku; Eero Polvinen; Anna Vuorimaa; Johanna Rokka; Marjo Nylund; Eero Rissanen; Laura Airas
Journal:  Brain       Date:  2020-12-05       Impact factor: 13.501

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.